
Buy, $247 target: the price assumes clients leave, yet contract value is growing
We initiate with a Buy and a 12-month target of $247.12, a 28.6% total return. Gartner sells research and advice to more than 13,000 enterprises. It bills up front, mostly on multi-year contracts. The price assumes clients leave, but contract value (CV, the annual value of subscriptions) is growing again at 2.5%.
- Contract value has turned. Growth rose from 1.0% to 2.5% in two quarters. One more point of CV growth adds $15.29 a share.
- EPS grows 16% a year to FY28E, 85% of it from a smaller share count. FY27E adjusted EPS is $17.49 on 58.3m shares, against 61.7m in consensus.
- The price implies decline. At 11.0x FY27E EPS, CV must fall 0.3% a year to FY35E. We model growth of 3.6%.
What the market is missing. We are 6.9% above consensus on FY27E EPS ($17.49 against $16.36) and 1.1% below on revenue. Our edge is contract value durability. Buybacks explain most of the EPS gap.
Catalysts. The FY27 outlook in early February 2027 settles the margin debate. Further rises in CV would close the valuation gap.
Valuation and target. A discounted cash flow, cross-checked at 15.0x FY27E EPS. Bear, base and bull are $133.40, $243.01 and $315.65 today, weighted 30/50/20. Upside to downside is 3.4x on 12-month values.
Risks. Generative AI replacing seats (−$21.14 a share), a margin reset (−$12.07) and rates above 5% (−$18.72).
| US$m, Dec year end | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 6,267 | 6,497 | 6,438 | 6,593 | 6,788 |
| Growth y/y | 6.1% | 3.7% | −0.9% | 2.4% | 2.9% |
| Adj. EBITDA | 1,556 | 1,611 | 1,640 | 1,675 | 1,744 |
| Margin | 24.8% | 24.8% | 25.5% | 25.4% | 25.7% |
| Net income | 1,254 | 729 | 943 | 957 | 992 |
| Adj. EPS ($) | 14.09 | 13.17 | 15.19 | 17.49 | 20.57 |
| Growth y/y | – | −6.5% | 15.3% | 15.2% | 17.6% |
| Free cash flow | 1,383 | 1,175 | 1,240 | 1,265 | 1,306 |
| At $192.15 | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P/E (adj.) | 13.6x | 14.6x | 12.7x | 11.0x | 9.3x |
| EV/EBITDA | 8.8x | 8.5x | 8.3x | 8.1x | 7.8x |
| EV/sales | 2.2x | 2.1x | 2.1x | 2.1x | 2.0x |
| FCF yield | 11.3% | 9.6% | 10.1% | 10.3% | 10.6% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Buyback yield | 6.0% | 16.2% | 13.2% | 13.8% | 13.8% |
| Net debt/EBITDA | 0.3x | 0.8x | 0.9x | 1.2x | 1.4x |
| P/E at $247 target | 17.5x | 18.8x | 16.3x | 14.1x | 12.0x |
Source: Company filings; Penmark Research model, 16 Nov 2026. Adjusted EPS adds back acquired-intangible amortisation and charges but keeps stock pay as a cost; adjusted EBITDA excludes stock pay. FY27E revenue growth of 2.4% includes the divested business in the FY26E base (2.7% excluding it). Right: multiples at the 13 Nov 2026 price; last row at our target. P/B and ROE are not meaningful (negative equity). Shaded = estimates.
Our base case is worth $243; upside is 3.4x downside on 12-month values
Source: Yahoo Finance weekly closes; Penmark Research model, 16 Nov 2026. Values today rolled forward 12 months at the 10.0% cost of equity (no dividend).
Retention above 100%; CV growth 6.5% by FY29E; margin 28%. Worth $315.65 today.
CV growth 3.0% in FY27E, 4.0% in FY29E-FY31E, fading to 3.0% by FY35E; margin 26%. Worth $243.01 today.
AI and layoffs cut seats; CV falls 1.5% by FY29E; margin 22%. Worth $133.40 today.
| US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Revenue | 6,267 | 6,497 | 6,438 | 6,593 | 6,788 |
| Adjusted EBITDA | 1,556 | 1,611 | 1,640 | 1,675 | 1,744 |
| Stock compensation | 155 | 156 | 171 | 171 | 176 |
| Depreciation and amort. | 202 | 200 | 184 | 185 | 183 |
| Operating income | 1,156 | 1,026 | 1,292 | 1,319 | 1,385 |
| Net interest | −69 | −61 | −88 | −91 | −113 |
| Net income | 1,254 | 729 | 943 | 957 | 992 |
| Adjusted net income | 1,103 | 996 | 999 | 1,019 | 1,053 |
| Cash flow, US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash from operations | 1,485 | 1,290 | 1,325 | 1,364 | 1,408 |
| Capital expenditure | −102 | −115 | −85 | −99 | −102 |
| Free cash flow | 1,383 | 1,175 | 1,240 | 1,265 | 1,306 |
| FCF margin | 22.1% | 18.1% | 19.3% | 19.2% | 19.2% |
| FCF / net income | 1.10x | 1.61x | 1.32x | 1.32x | 1.32x |
| Share repurchases | 735 | 1,991 | 1,620 | 1,693 | 1,689 |
| Closing cash | 1,933 | 1,723 | 1,445 | 1,000 | 600 |
| Net debt | 527 | 1,282 | 1,555 | 2,000 | 2,400 |
| Balance sheet, US$m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash | 1,933 | 1,723 | 1,445 | 1,000 | 600 |
| Fees receivable | 1,696 | 1,685 | 1,727 | 1,774 | 1,826 |
| Goodwill, intangibles | 3,340 | 3,077 | 2,994 | 2,915 | 2,837 |
| Total assets | 8,535 | 8,085 | 7,661 | 7,193 | 6,781 |
| Deferred revenue | 2,763 | 2,810 | 2,889 | 2,967 | 3,054 |
| Long-term debt | 2,460 | 2,977 | 2,981 | 2,981 | 2,981 |
| Total liabilities | 7,176 | 7,765 | 7,824 | 7,937 | 8,063 |
| Stockholders' equity | 1,359 | 320 | −163 | −744 | −1,282 |
| Per share and KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Diluted shares (m) | 78.3 | 75.6 | 65.9 | 58.3 | 51.2 |
| Adjusted EPS ($) | 14.09 | 13.17 | 15.19 | 17.49 | 20.57 |
| Reported EPS ($) | 16.00 | 9.65 | 14.32 | 16.43 | 19.38 |
| Dividend per share ($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF per share ($) | 17.66 | 15.54 | 18.83 | 21.71 | 25.52 |
| CV growth, year-end | 8.0% | 1.0% | 2.8% | 3.0% | 3.5% |
| Insights growth | 6.9% | 5.0% | 2.2% | 2.1% | 2.4% |
| Conferences growth | 15.4% | 10.5% | 10.7% | 7.0% | 6.0% |
Source: Company filings; Penmark Research model, 16 Nov 2026. FY24A–FY25A reported; shaded = estimates (E). Net debt is principal less cash; FY24A uses carrying value. FY26E adjusted EBITDA includes $5m from Digital Markets before its 5 Feb 2026 sale; FY27E onward excludes it. Bold = totals; italic = ratios.
Our FY27E EPS is 6.9% above consensus, mostly because we assume fewer shares
| Growth and margins, % | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Sales | 6.1% | 3.7% | −0.9% | 2.4% | 2.9% |
| Adjusted EBITDA | 4.9% | 3.5% | 1.8% | 2.1% | 4.2% |
| Operating income | −6.5% | −11.3% | 26.0% | 2.0% | 5.0% |
| Adjusted EPS | – | −6.5% | 15.3% | 15.2% | 17.6% |
| Free cash flow | 31.4% | −15.0% | 5.5% | 2.1% | 3.2% |
| Margins | |||||
| Adjusted EBITDA | 24.8% | 24.8% | 25.5% | 25.4% | 25.7% |
| Operating income | 18.4% | 15.8% | 20.1% | 20.0% | 20.4% |
| Free cash flow | 22.1% | 18.1% | 19.3% | 19.2% | 19.2% |
| Stock pay / sales | 2.5% | 2.4% | 2.7% | 2.6% | 2.6% |
| Leverage and valuation | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Leverage and cash | |||||
| Net debt / EBITDA | 0.3x | 0.8x | 0.9x | 1.2x | 1.4x |
| Gross debt / EBITDA | – | 1.9x | 1.8x | 1.8x | 1.7x |
| EBITDA / net interest | 22.4x | 26.6x | 18.6x | 18.4x | 15.4x |
| FCF / net income | 1.10x | 1.61x | 1.32x | 1.32x | 1.32x |
| At $192.15 | |||||
| P/E (adjusted) | 13.6x | 14.6x | 12.7x | 11.0x | 9.3x |
| EV / EBITDA | 8.8x | 8.5x | 8.3x | 8.1x | 7.8x |
| FCF yield | 11.3% | 9.6% | 10.1% | 10.3% | 10.6% |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| P/E at $247 target | 17.5x | 18.8x | 16.3x | 14.1x | 12.0x |
Source: Company filings; Penmark Research model, 16 Nov 2026. Growth for FY24A is against FY23A. FY27E sales growth of 2.4% includes the divested business in the FY26E base; excluding it, 2.7%. Net debt is debt principal less cash; FY24A uses carrying value. Returns on equity are not meaningful because equity is negative. Multiples at the 13 Nov 2026 price; last row at our target.
| Ours vs consensus | FY26E | FY27E |
|---|---|---|
| Revenue excl. divested, US$m | ||
| Penmark estimate | 6,419 | 6,593 |
| Consensus | 6,430 | 6,670 |
| Prior-year period | 6,270 | 6,419 |
| Diff. vs consensus | −0.2% | −1.1% |
| Growth y/y (Penmark) | +2.4% | +2.7% |
| Adjusted EBITDA excl. divested, US$m | ||
| Penmark estimate | 1,635 | 1,675 |
| Consensus | 1,608 | 1,679 |
| Prior-year period | 1,580 | 1,635 |
| Diff. vs consensus | +1.7% | −0.3% |
| Growth y/y (Penmark) | +3.5% | +2.4% |
| Adjusted EPS, $ | ||
| Penmark estimate | 15.19 | 17.49 |
| Consensus | 14.99 | 16.36 |
| Prior-year period | 13.17 | 15.19 |
| Diff. vs consensus | +1.3% | +6.9% |
| Growth y/y (Penmark) | +15.3% | +15.2% |
Source: Yahoo Finance (revenue, EPS; 16 Nov 2026), MarketScreener (EBITDA; 21 Oct 2026, before the 3 Nov guidance raise); Penmark Research model. FY26E guidance floors: revenue $6,405m, EBITDA $1,615m, EPS $14.65.
Source: Company filings (A); Penmark Research estimates (E); Yahoo Finance consensus, 16 Nov 2026. Actual to FY25A, estimates from FY26E; growth FY26E +15.3%, FY27E +15.2%, FY28E +17.6%.
Gartner is the cheapest of its peer group on earnings, and the discount is wider than its growth gap explains
| Gartner vs peers | IT | Median | Diff. |
|---|---|---|---|
| Valuation | |||
| NTM P/E | 12.1x | 24.4x | −51% |
| PEG (P/E / EPS growth) | 0.74x | 2.10x | −65% |
| Growth and returns | |||
| Revenue CAGR, 3y fcst | 3.0% | 6.4% | −3.5pp |
| EPS CAGR, 3y fcst | 16.3% | 11.2% | +5.1pp |
| ROIC | 34.0% | 17.9% | +16.1pp |
| Risk | |||
| Beta, 5y | 0.91 | 0.96 | −0.05 |
| Net debt / equity | 14.0% | 13.0% | +1.0pp |
Source: S&P Global via StockAnalysis, 13 Nov 2026; Penmark Research model. Peers: Verisk, FactSet, S&P Global, Moody's, MSCI, Thomson Reuters, Broadridge, Morningstar. NTM = next twelve months. ROIC = return on invested capital. Gartner growth is our base case, FY26E–FY29E.
- Feb 2027Q4 FY26 results and FY27 outlook. We expect a 25.4% EBITDA margin and EPS of $17.49; consensus is $16.36.
- May 2027Q1 FY27 results. CV growth near 3% from pricing and steadier retention.
- Aug 2027Q2 FY27 results. GTS retention above 100% is upside worth $15.29 a share; we hold near 98%.
- Nov 2027Q3 FY27 results. First full year of the 3% price rise; our target date.
Source: Company calls, 3 Nov 2026; Penmark Research model. Result dates are expected, not confirmed.
- AI replaces seats. CV growth 1.5pt lower each year. Likelihood 35%; −$21.14/share.
- Rates stay above 5%. Discount rate rises 0.5pt. Likelihood 30%; −$18.72/share.
- Margin reset in FY27 guide. EBITDA margin 1.0pt lower. Likelihood 30%; −$12.07/share.
- Upside risk: retention above 100%. CV growth 1.0pt higher. Likelihood 35%; +$15.29/share.
Source: Penmark Research model, 16 Nov 2026.
Source: Signals key metrics, 15 quarter-ends with data, Mar 2021 to Sep 2026 (last point 30 Sep 2026; GAAP EPS, last four quarters). Bands are the average and ±1 and ±2 standard deviations (SD) of the series.
Source: S&P Global via StockAnalysis, 13 Nov 2026; Penmark Research. Fit on the eight peers only.
Six charts show a recovering business priced as a shrinking one
The stock follows contract value, not revenue. Retention is mending, buybacks are shrinking the share count, and the market has cut the multiple more than earnings justify.
Source: Signals KPIs; Yahoo Finance quarter-end closes. Correlation of levels, eight quarters, Dec 2024 to Sep 2026.
Source: Company supplements and calls, via Signals KPIs. Wallet retention = share of last year's spend still collected.
Source: Company filings (A); Penmark Research estimates (E).
Source: Yahoo Finance consensus (revenue, EPS), 16 Nov 2026; MarketScreener (EBITDA), 21 Oct 2026; Penmark Research model.
Source: Signals, 12 quarter-ends with data, Mar 2021 to Sep 2026 (others not plotted). Last point: trailing, 30 Sep 2026; at $192.15 it is 8.2x (FY26E 8.3x). EV = enterprise value; band = average ±1 standard deviation.
Source: Yahoo Finance; company releases (last-four-quarter adjusted EPS $14.72 to $15.22); Penmark Research analysis. No dividend is paid.
The market and we disagree on three debates; the AI debate is worth the most
Three disagreements with the market decide the stock. Each one has a dated test within twelve months, and each is worth a number we can state per share.
| Debate | Market view | Penmark view | Evidence | What would change our view | Resolves |
|---|---|---|---|---|---|
| AI and the seat base | Generative AI cuts seats, so contract value (CV) growth runs 1.5pt a year lower | CV grows 3.0% in FY27E and 4.0% by FY29E. Value $243.01 a share against $221.87 at the market view | Ex-federal CV growth 4.0% (Q4 FY25), 3.3%, 2.8% (Q3 FY26). GTS retention 96% to 98%. Analyst questions on AI: 6 of 48 | Q4 FY26 print and FY27 guide show CV growth below 2.5% | Feb 2027 |
| Margins in FY27 | Analyst rehiring and sales investment cut the EBITDA margin by 1pt from FY27 | 25.4% in FY27E, 26.0% by FY29E. Value $243.01 against $230.93 | FY26 margin floor raised three times, to 25.2%. Our FY26E is 25.5%. Rehiring analysts adds cost over several quarters | FY27 guide implies a margin below 24.5% | Feb 2027 |
| Long-run growth | Terminal growth is 2%, because seats stop growing | 3.0%, set by a price rise of about 3% on a flat seat base. Value $243.01 against $229.02 | Price rise from 2 Nov 2026 is near 3%, the low end of the 3-4% history. Standard terms held | Price rise below 2% or retention below 97% through 2027 | Nov 2027 |
Source: Penmark Research model, 16 Nov 2026 (values at 13 Nov 2026, base case); company Q3 FY26 call, 3 Nov 2026; Signals KPIs. GTS = Global Technology Sales; ex-federal = excluding US federal government clients.
Source: Penmark Research model, 16 Nov 2026; base case valued at 13 Nov 2026; each debate changed alone.
How the debates fit the thesis
The AI debate is worth the most and drives the bear case. It is $21 a share, against $12 for margins and $14 for long-run growth. The three gaps sum to $47, which is most of the $51 between our base value and the price. The rating turns Hold only at a 59.7% bear weight.
Why the market may be wrong
The price already assumes shrinking subscriptions. It implies CV growth of −0.3% a year to FY35E, below even the AI bear case of 1.5pt less growth. Today the data point the other way: retention is up and CV growth has risen for two quarters.
Source: Company calendar pattern of prior years; Penmark Research. Dates are expected, not confirmed.
The market prices Gartner's $5.3bn of subscriptions as if they will shrink
Gartner sells research and advice to more than 13,000 enterprises. Its contract value is growing again, yet the shares trade at 11 times next year's earnings.
The scene
On 3 November 2026 Gartner reported contract value growth of 2.5%, up from 1.0% in the first quarter, and raised its profit guidance. The shares still fell 13% that day. Contract value (CV) is the yearly value of all subscription contracts, and the number Gartner treats as most important.
CV grew 8% in 2024 and 1% in 2025. Investors began to ask whether free artificial intelligence (AI) tools could do its analysts' work.
What it actually does
Gartner's analysts study markets and write up what they find. Leaders in technology, marketing and sales pay for that research and for analyst calls. The same clients buy conference places and hire its consultants.
How the money comes in
Clients pay up front and usually renew; over three-quarters of Insights contracts run multiple years. Insights, the subscription arm, was 81% of FY25 revenue (excluding the divested unit) and keeps about 77 cents of each dollar. Revenue grows when clients renew, add seats or accept a price rise, about 3% from 2 November 2026.
Where the story turns
Gartner bought CEB in 2017 in a deal valued at about $3.5bn. Wallet retention among business clients fell from 106% at the end of 2024 to 99% at the end of 2025. Management answered with cash: it sold Digital Markets for $110.0m ($99.8m net cash received) in February 2026 and bought back $1.99bn of stock in FY25.
Why it works, and why it might not
Clients stay because the research is built into how they buy technology. Technology-client wallet retention, the share of last year's spend still collected, rose from 96% at end-2025 to 98% in Q3 FY26. The break point is the AI debate: if AI tools replace seats, CV shrinks, and our bear case values the shares at $133.40.
One customer, start to finish (illustrative averages from company data; not a single named client). Source: Company filings and calls, 3 Nov 2026; Penmark Research model.
Insights earns four of every five dollars, and a quarter of revenue turns into EBITDA
Gartner sells one thing, trusted research, in three ways. A subscription is the core, and events and consulting are sold to the same clients.
Source: Company filings and press releases, 1979 to Feb 2026; revenue of the divested unit from the FY25 10-K (Penmark Research model).
Source: Company filings (9M FY26A); Penmark Research model, FY26E. Adjusted EBITDA includes $5m from the divested unit. Interest and other is net of one-off gains.
Source: Signals KPIs from company supplements, quarter to 30 Sep 2026.
Source: Penmark Research model, FY26E.
Source: Company FY25 10-K, rounded; other international derived as the remainder of $6.50bn.
Gartner is the scale leader; AI tools, not rivals, are the threat
Gartner leads a small field of research rivals by scale and growth. The open question is whether AI tools take away the cheap end of what it sells.
| Competitor | Where it overlaps | What is different |
|---|---|---|
| Forrester | Subscription research, advice and events | Closest business model; contract value down 3.5%; 9M GAAP operating loss $12.9m |
| IDC | Technology research, market data, advisory, events | Strong in quantitative market data and forecasts |
| Info-Tech Research Group | IT research, advisory and software reviews | Practical blueprints for completing IT projects |
| Everest Group, ISG | Provider research, sourcing and governance | Research is bundled with execution services |
| McKinsey, Accenture | Technology strategy and transformation | Project advice, not recurring research subscriptions |
| Generative AI tools | Answers to questions once taken to analysts | The question is whether answers are enough without proprietary data and expert calls |
Source: Company websites and filings; Gartner 10-K; industry commentary to Nov 2026. Gartner's share of IT research and advisory spending is not published.
Source: Penmark Research model (Gartner); Forrester Q3 2026 release, guide $350m-$360m; ISG Q3 2026 release, implied $255.8m-$256.8m. Mixes of research, consulting and events differ.
Source: Gartner Q3 FY26 release; Forrester Q3 2026 release. Definitions differ slightly between the two companies.
How big is the market?
Gartner serves a much wider market than research alone. Gartner cites an addressable opportunity of about $200bn across technology, finance, HR, legal, marketing and sales. That is potential demand, not what clients spend on research today. Against it, $5.3bn of contract value is about 2.7%, but that is penetration, not market share.
What threatens it?
Artificial intelligence (AI) tools could make routine answers cheap. Barclays cut Gartner to Underweight on 6 November 2026, citing ex-federal contract value growth of 2.8% against the roughly 4% exit rate Gartner had flagged, a Q4 pickup to only about 3%, and low-single-digit growth in 2027. On the other side, Gartner's digital engagement and analyst inquiries both rose in Q2 and Q3 FY26 (engagement +140bp), and it sells its own AI interface, AskGartner.
The CEO and CFO own $252m of stock, but pay is tied to contract value, not per-share profit
| Executive | Tenure | How they are paid | What they own |
|---|---|---|---|
| Eugene HallChairman and CEO | 22.3 yrsCEO since Aug 2004, chair since Jul 2024. Prior: Automatic Data Processing. | $19.23m total, FY25 86% equity, 8% cash bonus. Bonus: EBITDA 50%, revenue 50%. | $234.4m 1.8%1,219,897 shares; 238x salary. No open-market trades in the Form 4 sample. |
| Craig SafianEVP and CFO | 12.4 yrsCFO since Jun 2014; 23+ years at Gartner. Prior: Headstrong. | $6.52m total, FY25 75% equity, 13% cash bonus. Same bonus metrics. | $17.7m 0.1%92,253 shares; 25x salary. No open-market trades in the sample. |
| Scott HenselEVP, Global Services and Delivery | 6.0 yrsIn role since Nov 2020; joined 2017. Prior: Terex. | $4.35m total, FY25 69% equity, 16% cash bonus. Same bonus metrics. | $6.1m 0.05%31,591 shares; 10x salary. No open-market trades in the sample. |
| Thomas KimEVP, Chief Legal Officer | 3.6 yrsIn role since Apr 2023. Prior: Thomson Reuters (chief legal officer). | $3.86m total, FY25 65% equity, 18% cash bonus. Same bonus metrics. | $1.4m 0.01%7,236 shares; 2x salary. No open-market trades in the sample. |
| Robin KranichEVP, Chief HR Officer | 18.5 yrsIn role since May 2008; 31+ years at Gartner. | $4.35m total, FY25 69% equity, 16% cash bonus. Same bonus metrics. | $5.6m 0.04%29,204 shares; 10x salary. Sold 3,278 shares at $196.50 ($0.64m) on 27 Aug 2026. |
Source: Proxy statement (DEF 14A) filed 15 Apr 2026 for FY25; SEC Form 4 filings, 7 Aug to 10 Nov 2026. Hensel and Kranich were granted identical awards in the proxy summary compensation table (stock $2.09m, options $0.90m, bonus $0.70m); totals differ only slightly and both round to $4.35m, so both show about 69% equity and 16% cash bonus. Holdings: proxy table at 2 Apr 2026 (67.5m shares) at $192.15 (13 Nov 2026), beneficial ownership. 2025 bonus paid at 119.6% of target; share awards earned at 82.1%.
Source: SEC Form 4 filings, 7 Aug to 10 Nov 2026 (open-market sales, code S). Sales may be pre-arranged; we draw no inference on intent.
Source: Company cash flow statements, FY21 to FY25: operating cash flow $6,345m plus FY25 debt raised $551m. Other is derived: acquisitions, FX and cash build.
Does pay reward per-share value?
Partly. Equity is 88% of CEO target pay (86% of reported pay), 70% of it in share units earned on contract value. No pay metric is per share. Units were earned at 82.1% for 2025, when CV grew 1.0% reported and 4.0% excluding US federal clients.
Governance
The board is independent, but one person is chair and CEO. 12 of 13 directors are independent. A clawback policy meets NYSE rules, and the CEO must hold shares worth six times salary.
The shares trade on contract value growth, which moves them more than the market does
The shares trade on contract value, not on the market or on earnings. Two drivers passed at least two of four tests, and both measure whether subscriptions are shrinking.
| What moves the stock | Tests passed | Market reaction against our model value | Debate | Next number |
|---|---|---|---|---|
| Contract value growth | Three of four tests | Each 1pt of CV growth moved the shares 8.5% ($16) across all seven results days, 4.6% ($9) excluding 4 Aug 2026. Model: $15.29 | AI and the seat base | Q4 FY26 CV growth, Feb 2027 |
| Technology wallet retention | Two of four tests; retention vs price, correlation 0.86 | No clean results-day signal: the 4 Aug 2026 jump came with an EPS beat and guidance raise. Model: $15.29 if above 100% | AI and the seat base | Q4 FY26 retention, Feb 2027 |
Source: Yahoo Finance daily closes, Nov 2024 to Nov 2026; Signals KPIs; Q&A tagged from eight call transcripts; Penmark Research model, 16 Nov 2026. Reaction is a regression slope on seven results days, so treat it as approximate.
Source: Yahoo Finance; Signals KPIs; results days 6 May 2025 to 3 Nov 2026 (seven events; the Feb 2025 print has no prior CV change). The 4 Aug 2026 move also carried an EPS beat and a guidance raise; without it the correlation falls from 0.65 to 0.47. The fit is Penmark analysis.
Source: Yahoo Finance daily returns, 750 trading days to 17 Nov 2026; S&P 500, IGV software ETF, 10-year yield. R-squared = share of daily price variance explained.
Source: Signals call transcripts, eight calls from 4 Feb 2025 to 3 Nov 2026; 48 analyst question paragraphs tagged by Penmark Research.
Test results in brief
The share price follows CV growth, and more tightly than it follows the market. The level of quarter-end CV growth and the price have a correlation of 0.92 over eight quarters. On results days the correlation of the move with the change in CV growth is 0.65 (0.47 excluding 4 Aug 2026). Results days account for 35% of squared daily returns.
Retention questions came up nine times in 48. Our read: the stock trades on whether subscriptions are shrinking, not on earnings. EPS rose while the multiple fell.
One point of extra contract value growth is worth $15 a share; results days imply $9 to $16
Each driver is a claim, with the market reaction, our model value and the next number.
Driver: contract value growth
The claim. CV growth, now 2.5%, will reach 3.0% in FY27E, and that is worth more than the price implies.
What the market does. On results days the shares moved about 8.5% per point of change in CV growth with all seven days (about $16 a share at $192.15), and about 4.6% (about $9) excluding 4 Aug 2026.
What our model says. One extra point of CV growth a year is worth $15.29 a share. Our $15.29 sits inside the $9 to $16 that results days imply.
Debate. The AI and seat base debate.
Next number. Q4 FY26 CV growth, Feb 2027. We expect 2.8%; consensus is not published. A 1pt miss costs about 4.6% to 8.5%.
Driver: technology wallet retention
The claim. Retention among technology clients has turned; our base case holds it near 98%, and passing 100% is the upside case.
What the market does. Retention fell from 102% to 96% and the shares fell with it; its level and the price have a correlation of 0.86 over eight quarters. The 22.6% jump on 4 Aug 2026 came with adjusted EPS of $4.37 against about $3.77 expected and a 2026 EPS guide raised to $14 from $13.25, so we do not credit retention.
What our model says. Retention back above 100% is our upside case, worth $15.29 a share. It overlaps with the CV growth driver and is not additive.
Debate. The AI and seat base debate.
Next number. Q4 FY26 retention, Feb 2027. Q3 was 98%; our model does not forecast it, and the company gives no guidance on it.
| Candidate | Why we dropped it |
|---|---|
| Macro and layoffs | Most-asked topic (11 of 48), but the market explains 8% of daily moves and no result day tracks it |
| US federal sales | 3 questions; federal is only 2-3% of CV, too small to explain a 13% move |
| Interest rates | Adding the 10-year yield lifts R-squared by only 0.2 points |
| Margins and hiring | 8 questions, but the FY26 EBITDA floor was raised three times and the shares still fell on 3 Nov 2026 |
| Buybacks | 3 questions; they lift EPS, but the multiple change cost six times what earnings growth added |
Source: Yahoo Finance; Signals call transcripts and KPIs; Penmark Research analysis.
Source: Penmark Research model, 16 Nov 2026; FY27E-FY35E CV growth shifted by 1.0pt.
Source: Penmark Research model, 16 Nov 2026; base case valued at 13 Nov 2026; each input changed alone.
Contract value growth is recovering, and the price assumes it is not
What the market believes
The price implies CV growth averages about −0.3% a year to FY35E. Consensus FY27E revenue is $6,670m, which needs a recovery to near 4.5% by the end of FY27.
The evidence
- Reported data. CV growth rose from 1.0% to 2.5% in two quarters, and Q3 is the second rise in a row.
- KPIs. Technology wallet retention rose from 96% to 98%. Business wallet retention held at 99%.
- Calls. Management expects total CV growth to keep rising through year-end. Ex-federal growth is unlikely to reach 4% in 2026.
Source: Signals KPIs from company supplements, Dec 2024 to Sep 2026. Growth is y/y, FX-neutral.
| US$m | FY26E | FY27E |
|---|---|---|
| Revenue excl. divested, Penmark | 6,419 | 6,593 |
| Revenue, consensus | 6,430 | 6,670 |
| Difference | −0.2% | −1.1% |
| Contract value growth, Penmark | 2.8% | 3.0% |
Source: Yahoo Finance consensus, 16 Nov 2026; Penmark Research model. Consensus CV growth is not published.
What it is worth
CV growth of 3.0% in FY27E, 4.0% in FY29E-FY31E, fading to 3.0% by FY35E gives a base value of $243.01 a share. One extra point a year adds $15.29. At the market view, 1.5 points lower, the value is $221.87.
Signposts
- Feb 2027. Q4 FY26 CV growth at or above 2.8% confirms; below 2.5% disproves.
- May 2027. Q1 FY27 near 3%, from the 3% price rise (effective 2 Nov 2026) and steadier retention.
Source: Company calls, Q4 FY25, Q2 FY26 and Q3 FY26 (3 Nov 2026). Federal is 2% to 3% of CV.
Buybacks lift EPS well above revenue growth, and consensus under-models them
What the market believes
Consensus FY27E EPS of $16.36 implies about 61.7m shares, against our 58.3m, so it assumes less buying. The price implies 11.0x FY27E earnings.
The evidence
- Reported data. Weighted diluted shares fell from 78.3m in FY24 to 66.8m for 9M FY26, after $1.99bn of buybacks in FY25.
- Cash. Free cash flow (FCF) was 144% of net income in the first nine months of FY26, so buybacks are funded by operations.
- Calls. Management guides to a three-year EPS growth rate above 12% from FY25, a floor of $18.50 for FY28.
Source: Penmark Research model: adjusted net income $996m on 75.6m shares (FY25A) and $1,052m on 51.2m shares (FY28E). Split is Penmark arithmetic.
| Per share | FY26E | FY27E |
|---|---|---|
| Adjusted EPS, Penmark | 15.19 | 17.49 |
| Adjusted EPS, consensus | 14.99 | 16.36 |
| Difference | +1.3% | +6.9% |
| Diluted shares, Penmark (m) | 65.9 | 58.3 |
| Share count, consensus (m) | – | ~61.7 |
Source: Yahoo Finance consensus, 16 Nov 2026; Penmark Research model. Consensus share count is implied by consensus EPS and net income.
What it is worth
Of the $1.13 FY27E gap to consensus, fewer shares add $0.95. Shares are 58.3m against about 61.7m. Net income adds $0.18 ($1,019m vs about $1,009m): our 25.4% margin offsets revenue $77m below consensus.
Signposts
- Feb 2027. A FY27 share count guide near 58m confirms; above 62m disproves.
- Each quarter. Repurchases of at least $400m.
Source: Company filings (A); Penmark Research estimates (E). FY26E buybacks include $400m in Q4.
Our forecasts rest on contract value growth, and every FY26E line clears guidance
The forecast starts with contract value, the one number that drives the subscription arm. Everything else follows from it, from the 3.0% in FY27E to the 4.0% peak in FY29E to FY31E.
Source: Penmark Research model, FY27E. Highlighted box is the driver that matters most; the revenue gap is the lag between contract value and recognised revenue.
Source: Company Q3 FY26 call, 3 Nov 2026 (guidance floors, ‘at or above’; revenue and EBITDA exclude the divested unit); Penmark Research model, 16 Nov 2026. Percent = Penmark FY26E over the floor.
Source: Penmark Research model, 16 Nov 2026; base case valued at 13 Nov 2026 (Sensitivities).
Revenue, costs and cash
Revenue grows 2.7% in FY27E and 3.4% by FY30E, as contract value growth rises to 4%. Insights revenue lags contract value because subscriptions are recognised evenly over the year.
Margin edges up from 25.4% to 26.0% by FY29E. Stock pay is 2.6% of revenue, depreciation 1.5% to 1.6% and capex 1.5%. Analyst rehiring is the main cost pressure.
Free cash flow stays near 19% of revenue. Deferred revenue adds $79m in FY27E. The model holds $3.0bn of debt and $600m of cash from FY28E.
Where we differ from consensus
- Revenue, FY27E, −1.1%. We assume CV growth of 3.0% at year-end; consensus implies about 4.5%.
- EBITDA, FY27E, −0.3%. Our margin is 25.4% against 25.2% for the Street, which offsets lower revenue.
- EPS, FY27E, +6.9%. We use 58.3m shares; consensus implies about 61.7m.
Two methods put fair value at $243 to $262 a share, against a $192.15 price
We value Gartner two ways. A ten-year cash flow model sets the base value, and a peer-based earnings multiple checks it.
Source: Penmark Research model, 16 Nov 2026; values at 13 Nov 2026; target is the 12-month value; Street targets: S&P Global via StockAnalysis, page updated 9 Nov 2026 (15 analysts).
Source: Penmark Research model, 16 Nov 2026. Price $192.15; weighted value $224.66.
| DCF, US$m | Base case |
|---|---|
| PV of FY26E-FY35E cash flows | 8,175 |
| PV of terminal value | 9,035 |
| Enterprise value, 30 Sep 2026 | 17,210 |
| Less: debt, deferred comp. and $500m operating cash, net of cash | −1,874 |
| Equity value | 15,336 |
| Diluted shares (m) | 63.838 |
| Value per share, 30 Sep 2026 | $240.23 |
| Value per share, 13 Nov 2026 | $243.01 |
| Terminal value share of EV | 52.5% |
Source: Penmark Research model, 16 Nov 2026. Weighted average cost of capital (WACC) 9.17%; terminal growth 3.0%; return on new invested capital 20%.
Why a DCF is the main method
A one-year multiple cannot tell a 2% to 3% growth trough from a decline. A discounted cash flow (DCF) values the cash the business will produce over ten years. We use free cash flow after stock pay, FY26E to FY35E.
WACC is the blended return investors need from debt and equity. Terminal growth is the steady rate cash flow grows after FY35E.
The cross-check
FY27E EPS of $17.49 at 15.0x gives $262.35, 8.0% above the DCF. The multiple is the peer lower-quartile P/E of 18.8x less 20% for slower organic growth. The gap is under 15%, so the DCF stays the anchor.
| Peers | Gartner | Peer median | Difference |
|---|---|---|---|
| P/E, next twelve months | 12.1x | 24.4x | −51% |
| Revenue growth, 3-year CAGR | 3.0% | 6.4% | −3.5pp |
| Adjusted EPS growth, 3-year CAGR | 16.3% | 11.2% | +5.1pp |
| Return on invested capital | 34.0% | 17.9% | +16.1pp |
| Beta | 0.91 | 0.96 | −0.05 |
Source: S&P Global via StockAnalysis, 13 Nov 2026; Penmark Research model. Peer median P/E shown at the last close; target P/E applies a 20% discount to the 18.8x lower quartile.
The price assumes Gartner shrinks forever, and the target needs only modest growth
Source: Penmark Research model, 16 Nov 2026; base case valued at 13 Nov 2026 (Scenarios).
Source: Penmark Research model, 16 Nov 2026 (Market Check). Each solve changes one input and holds the others at base. Values in percent.
| Reconciliation | US$/share |
|---|---|
| Probability-weighted value, 13 Nov 2026 | $224.66 |
| Add: 12-month carry at 10.0% cost of equity | +$22.47 |
| 12-month price target | $247.12 |
| Share price, 13 Nov 2026 | $192.15 |
| Total return to target (rating basis) | +28.6% |
| Rating | Buy |
Source: Penmark Research model, 16 Nov 2026. Buy needs a total return above +10%. Carry is the expected price gain at the cost of equity; no dividend is paid.
What the price implies
A reverse DCF asks what the market must believe to justify today’s price. At $192.15 it needs contract value to shrink about 0.3% a year to FY35E. That is a worse outcome than 1.5pt lower growth, our AI bear driver.
Weights are our judgment, not measured odds. Hold needs a 59.7% bear weight.
| Case | Weight | Value | 12-month | Return | What has to happen |
|---|---|---|---|---|---|
| Bear | 30% | $133.40 | $146.74 | −23.6% | CV growth falls to −1.5% by FY29E; margin 22% |
| Base | 50% | $243.01 | $267.31 | +39.1% | CV growth 3.0% in FY27E, 4.0% in FY29E-FY31E, fading to 3.0% by FY35E; margin 26% |
| Bull | 20% | $315.65 | $347.22 | +80.7% | Retention above 100%; CV growth 6.5% by FY29E; margin 28% |
Source: Penmark Research model, 16 Nov 2026. Return is from $192.15 to each case’s 12-month value.
Source: Penmark Research model, 16 Nov 2026.
| FY27E | At $192.15 | At target |
|---|---|---|
| P/E, adjusted | 11.0x | 14.1x |
| EV / adjusted EBITDA | 8.1x | 10.2x |
| FCF yield | 10.3% | 8.0% |
| Peer median NTM P/E | 24.4x | 24.4x |
Source: Penmark Research model, 16 Nov 2026; S&P Global via StockAnalysis, 13 Nov 2026 (peer P/E).
Retention is the largest prize, and AI substitution is the largest risk
Source: Company calls, 3 Nov 2026 and earlier years; result dates are expected from prior-year timing and are not confirmed.
Source: Penmark Research model, 16 Nov 2026; base case $243.01 valued at 13 Nov 2026; each catalyst changed alone.
What would change the rating
The rating moves to Hold if the share price rises above $224.66, at an unchanged $247.12 target. It moves to Sell only if the price rises above $274.58 or the target falls below $172.94.
The bear case would need a 59.7% weight, from 30% today, to turn the rating to Hold. The thesis ends if contract value growth falls below 2.5% in the February result and the outlook cuts margins.
| Date | Event | Penmark expects | Street |
|---|---|---|---|
| Feb 2027 | Q4 FY26 and FY27 outlook | CV growth 2.8% or better; EBITDA margin 25.4% | Consensus FY27 margin 25.2% |
| May 2027 | Q1 FY27 | CV growth near 3% from pricing and steadier retention | Consensus FY27 revenue $6,670m |
| Aug 2027 | Q2 FY27 | GTS wallet retention near 98%; above 100% is the bull case | Partly priced in consensus |
| Nov 2027 | Q3 FY27 | First full year of the 3% price rise; 12-month target date | Consensus FY27 EPS $16.36 |
Source: Penmark Research model, 16 Nov 2026; Yahoo Finance consensus (revenue, EPS), 16 Nov 2026; MarketScreener (EBITDA), 21 Oct 2026.
| Risk | Likelihood | Value | Change tested |
|---|---|---|---|
| Generative AI replaces core research seats | 35% | −$21.14 | CV growth 1.5pt lower each year |
| Long rates stay above 5% | 30% | −$18.72 | Discount rate 0.5pt higher |
| FY27 outlook resets margins | 30% | −$12.07 | EBITDA margin 1.0pt lower |
| Tech layoffs and Gulf conflict cut renewals | 45% | −$2.72 | CV growth 0.5pt lower to FY28E |
| Upside risk: retention returns above 100% | 35% | +$15.29 | CV growth 1.0pt higher |
Source: Penmark Research model, 16 Nov 2026. Likelihoods are our judgment. Values are changes to the $243.01 base case.
Gartner is held by index and value funds, and the Street is mostly neutral
Source: SEC Form 13F filings, positions at 30 Sep 2026: ten largest of 670 13F filers by shares. BAMCO is an affiliate of Baron. As-of dates differ: BlackRock holds 5.0m shares at 30 Sep 2026 (13F) against 7.3m (10.8%) at 2 Apr 2026 (proxy). Totals can double-count shared positions, so we show no ownership percentages.
Source: Proxy statement (DEF 14A) filed 15 Apr 2026; 67,510,191 shares outstanding at 2 Apr 2026. Holders of more than 5% report to the SEC.
Source: S&P Global via StockAnalysis, page updated 9 Nov 2026, so it already includes Truist (4 Nov) and Barclays (6 Nov): 2 Strong Buy, 10 Hold, 2 Sell, 1 Strong Sell.
Source: S&P Global via StockAnalysis, page updated 9 Nov 2026, 15 analysts (same pull as Exhibit 69); Penmark Research model, 16 Nov 2026 (target and price at 13 Nov 2026).
What the holder list tells us
The 13F register is concentrated in index and value funds. Vanguard and BlackRock are index managers. BAMCO, Independent Franchise and Harris Associates are value-style managers.
| Trading and positioning | Value |
|---|---|
| Short interest, 30 Oct 2026 | 6.29m shares |
| Share of shares outstanding | about 9.9% |
| Days to cover | 5.8 |
| Average daily value traded, 3 months | $219m |
| 52-week closing range | $125.73 to $254.59 |
| Open-market insider sales, Aug to Nov 2026 | $1.47m |
| Open-market insider purchases | none |
Source: FINRA, 30 Oct 2026; Yahoo Finance, 13 Nov 2026; SEC Form 4 filings, 7 Aug to 10 Nov 2026.
Short interest and the Street
Short sellers cut their bets by 24% during the October rally. The stock then fell 13.2% on 3 November, so the next result can move it sharply either way.
The Street is cautious ahead of February. Truist moved to Hold on 4 November and Barclays to Underweight on 6 November. Our target is above every Street target.
Growth has slowed to 3.7%, and FY25 adjusted profit was well above GAAP
Source: Company filings, FY22 to FY25; growth on reported revenue including the divested operation. FY22 growth uses FY21 revenue of $4,734m.
Source: Company cash flow statements and income statements, FY22 to FY25. Free cash flow is operating cash flow less capex.
Source: Company filings. FY24 GAAP EPS includes a $300m insurance gain; FY25 includes $229m of impairments and other items. Adjusted EPS is company-defined.
| Adjusted to GAAP | FY24A | FY25A | 9M FY26A |
|---|---|---|---|
| Adjusted EPS | $14.09 | $13.17 | $11.28 |
| Diluted GAAP EPS | $16.00 | $9.65 | $10.66 |
| Gap, adjusted less GAAP | −$1.91 | +$3.52 | +$0.62 |
| Amortisation, $m | 90.2 | 82.3 | 60.1 |
| Impairments, $m | 0 | 229 | – |
| Gain on divestiture, $m | 0 | 0 | 6.8 |
| Insurance gain, $m | 300.0 | 0 | 0 |
Source: Company filings (10-K FY24 and FY25, 10-Q Q3 FY26) and releases; Penmark Research model, 16 Nov 2026.
Quality of earnings
Adjusted EPS excludes $82m of acquired-intangible amortisation and $229m of FY25 charges; stock pay stays in as a cost. Adjusted EBITDA adds stock pay back, so our DCF deducts it separately ($171m in FY27E).
FY24 GAAP profit was flattered by a $300m insurance gain. That is why GAAP EPS of $16.00 sat above adjusted EPS in that year.
Accounting choices to watch
- Deferred revenue. It adds $79m to FY26E free cash flow, so FCF excluding it is $1,161m.
- Buybacks. Equity turned negative, to −$35m, in September 2026, because repurchases exceed retained profit.
The model has revenue growing 2.4% to 3.4% a year while EPS compounds at 14% to 18%
| Annual model | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY31E | FY32E | FY33E | FY34E | FY35E |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement, US$m | |||||||||||
| Insights revenue | 5,073 | 5,185 | 5,294 | 5,424 | 5,584 | 5,762 | 5,947 | 6,130 | 6,303 | 6,465 | 6,615 |
| Conferences revenue | 645 | 714 | 764 | 810 | 854 | 897 | 937 | 975 | 1,014 | 1,049 | 1,086 |
| Consulting revenue | 552 | 520 | 536 | 554 | 574 | 594 | 615 | 636 | 655 | 675 | 695 |
| Total revenues | 6,497 | 6,438 | 6,593 | 6,788 | 7,012 | 7,253 | 7,499 | 7,741 | 7,972 | 8,189 | 8,397 |
| Revenue growth excl. divested | 5.0% | 2.4% | 2.7% | 2.9% | 3.3% | 3.4% | 3.4% | 3.2% | 3.0% | 2.7% | 2.5% |
| Adjusted EBITDA | 1,611 | 1,640 | 1,675 | 1,744 | 1,823 | 1,886 | 1,950 | 2,013 | 2,073 | 2,129 | 2,183 |
| Adj. EBITDA margin excl. divested | 25.2% | 25.5% | 25.4% | 25.7% | 26.0% | 26.0% | 26.0% | 26.0% | 26.0% | 26.0% | 26.0% |
| Stock-based compensation | 156 | 171 | 171 | 176 | 182 | 189 | 195 | 201 | 207 | 213 | 218 |
| Operating income | 1,026 | 1,292 | 1,319 | 1,385 | 1,458 | 1,568 | 1,642 | 1,695 | 1,746 | 1,793 | 1,839 |
| Interest expense, net | −61 | −88 | −91 | −113 | −142 | −156 | −172 | −178 | −178 | −178 | −178 |
| Net income | 729 | 943 | 957 | 992 | 1,026 | 1,101 | 1,146 | 1,183 | 1,223 | 1,260 | 1,295 |
| Adjusted net income | 996 | 999 | 1,019 | 1,053 | 1,087 | 1,117 | 1,146 | 1,183 | 1,223 | 1,260 | 1,295 |
| Diluted shares, average (m) | 75.6 | 65.9 | 58.3 | 51.2 | 45.5 | 41.0 | 36.8 | 32.9 | 29.2 | 25.8 | 22.6 |
| Adjusted EPS, US$ | 13.17 | 15.19 | 17.49 | 20.57 | 23.91 | 27.28 | 31.17 | 35.99 | 41.84 | 48.80 | 57.21 |
| Adjusted EPS growth | −6.5% | 15.3% | 15.2% | 17.6% | 16.3% | 14.1% | 14.3% | 15.5% | 16.2% | 16.6% | 17.2% |
| Diluted EPS, US$ | 9.65 | 14.32 | 16.43 | 19.38 | 22.57 | 26.89 | 31.17 | 35.99 | 41.84 | 48.80 | 57.21 |
Source: Company filings (FY25A); Penmark Research model, 16 Nov 2026 (estimates shaded). Fiscal year ends 31 December. FY26E includes $19.4m revenue from the divested operation; later years exclude it. FY27E growth is 2.4% including it in the FY26E base and 2.7% excluding it.
| Cash flow and balance sheet | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E | FY31E | FY32E | FY33E | FY34E | FY35E |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow, US$m | |||||||||||
| Cash from operating activities | 1,290 | 1,325 | 1,364 | 1,408 | 1,457 | 1,489 | 1,525 | 1,571 | 1,617 | 1,659 | 1,700 |
| Capital expenditure | −115 | −85 | −99 | −102 | −105 | −109 | −112 | −116 | −120 | −123 | −126 |
| Free cash flow | 1,175 | 1,240 | 1,265 | 1,306 | 1,351 | 1,380 | 1,413 | 1,455 | 1,497 | 1,536 | 1,574 |
| Free cash flow / net income | 161.2% | 131.5% | 132.2% | 131.7% | 131.7% | 125.3% | 123.2% | 122.9% | 122.4% | 121.9% | 121.5% |
| Share repurchases, gross | 1,991 | 1,620 | 1,693 | 1,689 | 1,338 | 1,367 | 1,399 | 1,440 | 1,482 | 1,521 | 1,558 |
| Balance sheet, US$m | |||||||||||
| Cash | 1,723 | 1,445 | 1,000 | 600 | 600 | 600 | 600 | 600 | 600 | 600 | 600 |
| Deferred revenues | 2,810 | 2,889 | 2,967 | 3,054 | 3,155 | 3,264 | 3,374 | 3,483 | 3,587 | 3,685 | 3,778 |
| Long-term debt, net of fees | 2,977 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 | 2,981 |
| Stockholders' equity (deficit) | 320 | −163 | −744 | −1,282 | −1,424 | −1,515 | −1,586 | −1,656 | −1,723 | −1,786 | −1,846 |
| Net debt (principal less cash) | 1,282 | 1,555 | 2,000 | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 | 2,400 |
| Gross debt / adjusted EBITDA | 1.87x | 1.83x | 1.79x | 1.72x | 1.65x | 1.59x | 1.54x | 1.49x | 1.45x | 1.41x | 1.37x |
Source: Company filings (FY25A); Penmark Research model, 16 Nov 2026. Net debt is principal less cash; the model holds $3.0bn of debt and $600m of cash from FY28E.
Eight quarters show stable Insights revenue and contract value growth turning up
| US$m unless stated | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Insights revenue | 1,247 | 1,256 | 1,264 | 1,271 | 1,283 | 1,294 | 1,290 | 1,292 |
| Conferences revenue | 251 | 73 | 211 | 75 | 286 | 78 | 244 | 86 |
| Consulting revenue | 153 | 140 | 156 | 124 | 134 | 119 | 142 | 126 |
| Other (divested) | 64 | 66 | 56 | 55 | 50 | 19 | 0 | 0 |
| Total revenues | 1,715 | 1,534 | 1,686 | 1,524 | 1,753 | 1,511 | 1,676 | 1,505 |
| Adjusted EBITDA | 417 | 385 | 443 | 347 | 436 | 400 | 466 | 364 |
| Adjusted EPS, US$ | 5.45 | 2.98 | 3.53 | 2.76 | 3.94 | 3.32 | 4.37 | 3.59 |
| Free cash flow | 311 | – | – | 269 | 271 | 371 | 378 | 275 |
| Operating KPIs | ||||||||
| CV growth, FX-neutral | 8.0% | 7.0% | 4.9% | 3.0% | 1.0% | 1.0% | 1.7% | 2.5% |
| CV growth excl. US federal | – | – | – | – | 4.0% | – | 3.3% | 2.8% |
| Technology wallet retention | 102.0% | 101.0% | 99.0% | 98.0% | 96.0% | 97.0% | 97.0% | 98.0% |
| Business wallet retention | 106.0% | 105.0% | 104.0% | 102.0% | 99.0% | 98.0% | 99.0% | 99.0% |
Source: Company earnings releases, 10-Q filings and calls, Q4 FY24 to Q3 FY26. Technology (GTS) and Business (GBS) are the two client groups.
Source: Company earnings releases and 10-Q filings, Q4 FY24 to Q3 FY26. Excludes the divested operation. Conferences peaks in Q2 and Q4.
| US$m | FY23A | FY24A | FY25A | FY26E | FY27E |
|---|---|---|---|---|---|
| Insights | 4,516 | 4,829 | 5,073 | 5,185 | 5,294 |
| Conferences | 505 | 583 | 645 | 714 | 764 |
| Consulting | 515 | 559 | 552 | 520 | 536 |
| Other (divested) | 371 | 297 | 227 | 19 | 0 |
| Total revenues | 5,907 | 6,267 | 6,497 | 6,438 | 6,593 |
Source: Company filings (A); Penmark Research model, 16 Nov 2026 (E). FY26E includes $19.4m from Digital Markets, sold 5 Feb 2026.
| Gross contribution, US$m | FY24A | FY25A | 9M FY26A |
|---|---|---|---|
| Insights | $3,696.8 | $3,890.2 | $3,013.8 |
| Conferences | $281.4 | $322.8 | $205.6 |
| Consulting | $203.3 | $186.4 | $133.3 |
| Insights share of total | 88.4% | 88.4% | 89.9% |
Source: Company 10-K FY25 segment note and 10-Q Q3 FY26. Share is Insights over the three segments shown.
Adjusted profit differs from reported by up to $267m, and every adjustment is company-defined
| US$m unless stated | FY24A | FY25A | 9M FY26A |
|---|---|---|---|
| Adjusted net income | 1,103 | 996 | 753 |
| Net income, as reported | 1,254 | 729 | 712 |
| Adjusted less reported | −151 | +267 | +41 |
| Adjusted EPS, US$ | 14.09 | 13.17 | 11.28 |
| Diluted EPS, as reported, US$ | 16.00 | 9.65 | 10.66 |
| Adjusted EBITDA | 1,556 | 1,611 | 1,230 |
| Operating income, as reported | 1,156 | 1,026 | 976 |
Source: Company filings and earnings releases; Penmark Research model, 16 Nov 2026. Adjusted measures follow the company definitions.
Peer set
Verisk (VRSK), FactSet (FDS), S&P Global (SPGI), Moody’s (MCO), MSCI (MSCI), Thomson Reuters (TRI), Broadridge (BR) and Morningstar (MORN). Forrester is excluded as an anchor because its earnings are near zero.
Data sources and dates
Company filings: 10-K FY25 (filed 12 Feb 2026), 10-Q Q3 FY26 and proxy statement (15 Apr 2026). Earnings releases and calls to 3 Nov 2026. SEC Forms 4 to 10 Nov 2026 and Forms 13F at 30 Sep 2026. Yahoo Finance prices to 17 Nov 2026, with the model price of $192.15 at 13 Nov 2026; S&P 500 +12.2% is Yahoo Finance weekly closes, 14 Nov 2025 to 13 Nov 2026. Street ratings and targets: S&P Global via StockAnalysis, page updated 9 Nov 2026. Consensus revenue and EPS from Yahoo Finance, 16 Nov 2026; EBITDA from MarketScreener, 21 Oct 2026. Peer data from S&P Global via StockAnalysis. Penmark Research model dated 16 Nov 2026.
Methodology note
Archetype: recurring revenue. Insights subscriptions are 81% of revenue excluding the divested unit; contracts are billed up front and over three-quarters run multiple years. We value Gartner with a ten-year discounted cash flow after stock pay, cross-checked with FY27E adjusted EPS at 15.0x. The target is the probability-weighted value of the bear, base and bull cases at 13 Nov 2026 plus twelve months of carry at the 10.0% cost of equity.
The model uses 63.838m diluted shares at 30 Sep 2026. Debt is deducted at principal. Consensus FY27E EBITDA was dated 21 Oct 2026, before the 3 November guidance raise.
Glossary and ratio definitions
- Contract value (CV)
- The annualised value of subscription contracts. It is the main operating measure.
- Wallet retention
- The share of last year’s client spending still held this year, including upgrades and cancellations.
- Technology (GTS) and Business (GBS)
- The two client groups: technology leaders and business leaders such as finance and marketing.
- Free cash flow (FCF)
- Operating cash flow less capital spending.
- Adjusted EBITDA
- Earnings before interest, tax, depreciation and amortisation, as the company defines it.
- WACC
- Weighted average cost of capital: the blended return investors need from debt and equity.
- Terminal growth
- The steady rate cash flow grows after the last forecast year.
- Reverse DCF
- A discounted cash flow solved backwards for what the price implies.
- ROIC
- Return on invested capital: operating profit after tax over capital invested.
- P/E; EV/EBITDA
- Share price over earnings per share; enterprise value over EBITDA.
Analyst certification and important disclosures
Ratings
Ratings are based on the total return from the share price to our 12-month price target, including dividends (Gartner pays none). The price target is weighted across bull, base and bear scenarios.
| Buy | Total return to price target above +10% |
| Hold | Total return to price target from −10% to +10%, inclusive |
| Sell | Total return to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.